SuperworthMerck profit margin MRK
Gross, operating and net profit as a share of revenue over the last twelve months, from 2009.
- Net margin, 12 months
- 4.8%
- Operating margin, 12 months
- 9.6%
- Net margin on a year earlier
- −21.0 pts
- Peer median
- 9.8%
Over the twelve months to Jun 30, 2026, Merck kept 4.8% of its revenue as net profit, with an operating margin of 9.6% and a gross margin of 73.0%.
Five years earlier its net margin was 12.3%.
The median for 8 large drugmakers of a similar size is 9.8%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | 28.1% | 32.6% | 74.8% |
| FY2024 | 26.7% | 31.0% | 76.3% |
| FY2023 | 0.6% | 3.9% | 73.2% |
| FY2022 | 24.5% | 30.3% | 70.6% |
| FY2021 | 26.8% | 25.7% | 72.0% |
| FY2020 | 15.8% | 14.3% | 67.4% |
| FY2019 | 21.0% | 24.8% | 69.9% |
| FY2018 | 14.7% | 19.6% | 68.1% |
| FY2017 | 6.0% | 15.0% | 67.8% |
| FY2016 | 9.8% | 13.5% | 65.1% |
| FY2015 | 11.2% | 17.5% | 62.2% |
| FY2014 | 28.2% | 13.4% | 60.3% |
| FY2013 | 10.0% | 13.5% | 61.5% |
| FY2012 | 13.0% | 19.5% | 65.2% |
| FY2011 | 13.1% | 16.0% | 64.9% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | 4.8% | −21.0 pts | 9.6% | |
| Q1 FY26 | 13.6% | −13.7 pts | 18.2% | |
| Q4 FY25 | 28.1% | +1.4 pts | 32.6% | |
| Q3 FY25 | 29.6% | +10.4 pts | 33.7% | |
| Q2 FY25 | 25.8% | +3.8 pts | 30.0% | |
| Q1 FY25 | 27.3% | +23.5 pts | 31.5% | |
| Q4 FY24 | 26.7% | +26.1 pts | 31.0% | |
| Q3 FY24 | 19.2% | +11.5 pts | 21.6% | |
| Q2 FY24 | 22.0% | +16.6 pts | 24.7% | |
| Q1 FY24 | 3.8% | −18.8 pts | 6.9% | |
| Q4 FY23 | 0.6% | −23.9 pts | 3.9% | |
| Q3 FY23 | 7.8% | −18.1 pts | 13.1% |
Against its peers
Companies in Drug Manufacturers - General nearest Merck's size, closest first, today.
| Company | Profit margin |
|---|---|
| MRKMerck | 4.8% |
| ABBVAbbVie | 9.8% |
| AMGNAmgen | 23.0% |
| JNJJohnson & Johnson | n/m |
| GILDGilead Sciences | −10.6% |
| PFEPfizer | 6.8% |
| BMYBristol-Myers Squibb | 18.9% |
| LLYEli Lilly and | 33.5% |
| BIIBBiogen | 8.3% |
| Peer median | 9.8% |
Where Merck ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Merck
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.